Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

NCT07151872 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

CLDN18.2-positive Advanced Biliary Tract Cancer

Interventions

DRUG: QLS31905 for Injection
DRUG: Gemcitabine Hydrochloride for Injection
DRUG: Cisplatin for Injection
DRUG: QL2107 Injection
DRUG: Oxaliplatin Injection
DRUG: Capecitabine Tablets

Sponsor

Qilu Pharmaceutical Co., Ltd.